This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vaccine Hopes Rise Again: 4 Stocks to Watch
by Ritujay Ghosh
The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and Sanofi (SNY).
Moderna May Supply 40M Coronavirus Vaccine Doses to Japan
by Zacks Equity Research
Moderna (MRNA) is negotiating a deal with Japanese authorities for supply of its coronavirus vaccine in Japan, following a potential approval.
Moderna Stock Surges 260% YTD on Coronavirus Vaccine Progress
by Zacks Equity Research
Moderna (MRNA) is making significant progress in development of coronavirus vaccine. The vaccine is currently in phase III study.
Stock Market News for Aug 24, 2020
by Zacks Equity Research
Rally in large-cap technology-related firms helped the Nasdaq hit another record high this year on Friday.
BioNTech (BNTX) Looks Good: Stock Adds 10.2% in Session
by Zacks Equity Research
BioNTech (BNTX) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Is the Options Market Predicting a Spike in BioNTech (BNTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.
US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch
by Ritujay Ghosh
The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism
by Ritujay Ghosh
Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.
BioNTech SE Sponsored ADR (BNTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $77, marking a -0.1% move from the previous day.
BioNTech (BNTX) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
During BioNTech's (BNTX) upcoming Q2 earnings conference, investors will keep track of the advancement of its COVID-19 vaccine candidate being developed in partnership with Pfizer.
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
Coronavirus Vaccine Efforts Key to Moderna (MRNA) Q2 Earnings
by Zacks Equity Research
Moderna (MRNA) is progressing with coronavirus vaccine development. The company has initiated a late-stage study and investors will likely focus any preliminary data from the study
All Eyes on "The Swamp;" Plus Q2 Reports from PFE, MCD & More
by Mark Vickery
Senate Republicans on Capitol Hill have unveiled their long-awaited stimulus package to replace the CARES Act, which expires at the end of this week. Also, the Fed begins a two-day session.
HEALS Act & Earnings Data Deluge
by Zacks Equity Research
HEALS Act & Earnings Data Deluge
Coronavirus Vaccine Development Puts These Stocks in Focus
by Ritujay Ghosh
Moderna and Pfizer launches two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year.
The Zacks Analyst Blog Highlights: AstraZeneca, BioNTech, Pfizer, Cimarex Energy, Diamondback Energy, Centennial Resource Development and Bonanza Creek Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, BioNTech, Pfizer, Cimarex Energy, Diamondback Energy, Centennial Resource Development and Bonanza Creek Energy
Stock Market News for Jul 23, 2020
by Zacks Equity Research
Wall Street closed higher on Wednesday buoyed by good news from coronavirus treatment front and possible injection of fresh stimulus by the U.S. government.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Big Day for Q2 Earnings, U.S. Spends $1.95B on Pfizer Drug
by Mark Vickery
Q2 earnings season really hits the accelerator today; it's the single-biggest day of earnings reports for the quarter so far.
3 Small Biotechs in Focus on Promising Coronavirus Vaccine Data
by Zacks Equity Research
Pfizer (PFE) and AstraZeneca (AZN) announce promising data from early-stage coronavirus vaccine studies. Here we discuss three leading biotechs with potential to recshare price gains.
Stock Market News for Jul 21, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Monday as the tech rally resumed after the gap of a week.
Can Pfizer (PFE) Deliver a Beat in Coronavirus-Hit Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Pfizer's (PFE) performance when it reports second-quarter results.
The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi
Moderna Rallies on Encouraging Coronavirus Vaccine Study Data
by Zacks Equity Research
Moderna's (MRNA) coronavirus vaccine candidate achieves levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson